H.C. Wainwright raised the firm’s price target on Cardiff Oncology (CRDF) to $17 from $13 and keeps a Buy rating on the shares following the Q4 report. The firm views the totality of the data for onvansertib plus chemo as “highly promising.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRDF: